Immune Therapeutics Inc. To Present at JP Morgan Health Conference

ORLANDO, FL / ACCESSWIRE / January 11, 2016 / Immune Therapeutics Inc. (OTCQB: IMUN) CEO, Noreen Griffin, will be making a presentation at today’s JP Morgan Health Conference at the Fairmont hotel in San Francisco.

Her 30 minute presentation, which begins at 3:30 p.m. PST, will provide an overview of the company’s major 2015 milestones and will include the outlook for 2016. Immune Therapeutics will showcase the Company’s groundbreaking treatments for cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases, and showcase the 2016 product roadmap and global distribution strategy. The Company will also be participating in 1-on-1 meetings throughout the day.

Immune Therapeutics’ Naltrexone is an opioid antagonist used primarily in the management of alcohol and opioid dependence; the FDA approved Naltrexone in 1984 at 50mg. However, there is “Accumulating evidence suggests Low Dose Naltrexone (LDN) can promote health supporting immunomodulation, which reduces various oncogenic inflammatory autoimmune processes. The value of Naltrexone as an immune modulator was recognized by Dr. Ian Zagon at the University of Pennsylvania. The late Dr. Bernard Bihari, a Neurophysician from New York (who passed away on May 16th, 2010) began treating his patients in the late 1980s. Since that time, many doctors throughout the United States prescribe LDN for a number of indications including Multiple Sclerosis (MS), Parkinson’s disease, Crohn’s disease, HIV/AIDS, cancer and other autoimmune and inflammatory diseases.”

The mechanism of action of naltrexone, in autoimmune diseases and cancer, is still being researched, but there are theories as to the mechanism of action that both explain why LDN works on both autoimmune diseases and cancers, as well as inflammatory disease. According to Mark J. Donahue’s paper on LDN that uses interviews from Dr. David, Gluck, Dr. Jacquelyn McCandless, Dr. Jarred Younger, and Dr. Ian Zagon: “LDN is an opioid antagonist that not only blocks the reception of opiates, but also the body’s own endogenous opioids – endorphins. However, because LDN is administered in such a ‘low dose’ it is believed that LDN only briefly (for 3-4 hours) obstructs the effects of endorphins. Sensing an endorphin deficit, the hypothalamus signals for increased production of endorphins in what is called ‘the rebound effect.’ The rebound effect results in three things happening:

– Opioid receptor production increases in order to try and capture more endorphins.
– Opioid receptor sensitivity increases, also in order to try and capture more endorphins.
– Production of endorphins is increased in order to compensate for the perceived shortage.

Once LDN is metabolized by the liver and eliminated from the body (after 3-4 hours), the elevated levels of endorphins produced, as a result of the rebound effect, can now interact and bind with the more sensitive and more plentiful opioid receptors. These opioid receptors, are found throughout the body, including virtually every cell of the body’s immune system.”

About Immune Therapeutics, Inc.

Immune Therapeutics Inc [formally TNI Biotech, name change 2014] is a biotechnology company working to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.

Forward Looking Statements

This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by Immune Therapeutics may not proceed as contemplated, and by all other matters specified in Immune Therapeutic’s filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. Immune Therapeutics does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Immune Therapeutics’ filings with the Securities and Exchange Commission, including its recent periodic reports.

For more information please contact:

Mike King
Director, Princeton Research, Inc.
3887 Pacific St Las Vegas, NV 89121
Office: (702) 650-3000
Web: www.princetonresearch.com
FB: www.facebook.com/princetonresearch

SOURCE: Immune Therapeutics, Inc.

ReleaseID: 435503